Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes
Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes...and for combo use with a sulfonylurea.
Initially, it was approved only as add-on therapy for patients poorly controlled on insulin.
For initial therapy, Rezulin works about as well as metformin (Glucophage) or a sulfonylurea. It lowers blood sugar about 50 mg/dL...and reduces glycosylated hemoglobin (HbA1c) up to 1.5%.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote